+34 620 10 75 37info@nanbiosis.com

News

nanbiosis news

You are here : Home / News (Page 11)

NANBIOSIS U7 at the 15th IBEC Symposium October 2022

The MicrofabSpace and Microscopy Characterization Facility of IBEC, U7 unit of Nanbiosis, presented a stand and posters in the 15 edition of the annual IBEC’s Symposium which took place last October 19th in Barcelona. Researechers of this facility showed new microfabrication processes and microscopy tools, to worldwide researchers in the field of bioengineering.

The MicroFabSpace and Microscopy Characterization Facility is one of the most experienced services in the IBEC’s Core Facilities. With a cleanroom research space, specialized in the microfabrication and characterization of micro-structured devices focussed on bioengineering and a microscopy space specialized in the characterization of biological samples, it currently offers extensive services to internal and external users, going from design and consultancy to development and analysis of fabricated devices and biological samples.

Further nformation n NANBIOSIS youtube channel

• Read More

Microchannel capillarity pumping design by Prof. Guillermo Artana

On the 28th of October, we will be receiving the international visit at the  Unversity of Zaragoza from Dr. Guillermo Artana from Laboratorio de Fluidodinámica-Facultad de Ingeniería-Universidad de Buenos Aires. The title of the talk will be “Microchannel capillarity pumping design“.

The invited lecture is programed within the framework of the European project “Heart On chip based on induced pluripotent Stem cell Technology for personalized Medicine (CISTEM)” and counts with European funding: Horizon 2020 – Research and Innovation Framework Programme / H2020-MSCA-RISE-2017, grant agreement No.778354 in wich the University of Zaragoza participates through CIBER-BBN group TME lab – NANBIOSIS U13 Tissue & Scaffold Characterization Unit.

The event will take place at 12:00 in the Conference Hall bloque 1, planta 1,edif.I+D+I; Campus Rio Ebro, Zaragoza

• Read More

New edition of the course on characterization and preparation of particulate materials.

ICMAB-CSIC October 19th 2022

Amable Bernabé, from Nanbiosis U6 Biomaterial Processing and Nanostructuring Unit hosted from Monday, 3 October, to Wednesday, 5 October a course on “Characterization techniques for particulate materials”. The course counted with 10 participants from different CSIC centers.

The course was an introduction to different techniques to characterize nanoparticles and other particulate matter, including the basic fundamentals of these techniques, sample preparation, practical examples and results interpretation.    It is the fifth edition of the course, which started in 2018. Amable Bernabé, technician from the Soft Materials Service, prepares and offers this course to all the CSIC community, so everyone who needs it can learn new methods to characterize nanoparticles, the theory behind the techniques, and how to manage the lab equipment devoted to these techniques.   The course is offered every year through the CSIC training courses offered every year for all its staff. This year, the 10 participants were from CSIC centers of the Barcelona area: IMB-CNM, IDAEA, ICM and ICMAB, mainly.

Soft Materials Service – NANBIOSIS ICTS U6

The Soft Materials Service constitute the unit 6 of NANBIOSIS, the integrated infrastructure for the production and characterization of nanomaterials, biomaterials and systems in biomedicine, which has been recognized by Spanish Government as Unique Scientific-Technological Infrastructure (ICTS).

The Unit of NANBIOSIS provides equipment and technical assistance for the preparation and characterization of micro-and nanostructured soft molecular materials (molecular surfaces, micro- and nanoparticulate molecular materials, plastic films, dispersed systems, SAMs, etc..) with interest in different areas of application (biomedicine, electronics, energy storage and other chemical and material application areas).

The Soft Materials Service, with Amable Bernabé and David Piña as technicians, participate in many European projects and give service to the whole ICMAB community, apart from the Nanomol Research Unit, and also to other CSIC centers and research institutions and companies. In 2021, for example, 30 % of the users were external. Of these users, 14.3 % were from private companies, 58.9 % came from other research centers or universities, and 26.8 % from other ICMAB research units. 

This last April 2022, the Service Materials Service, which is part of Unit6 of the ICTS Nanbiosis and CIBER-BBN, obtained the ISO 9001:2015 Quality Certification, which ensures the quality of the service provided and helps to continue with its improvement and extension to future services.

Contents of the course

Theory:

  • Dynamic Light Scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments)
    • Size distribution
    • Z Potential 
  • Nanoparticle Tracking Analysis (NTA) with Nanosight NS300 (Malvern Instruments)
    • Size distribution
    • Particle concentration
    • Fluorescence
  • Light Scattering (LS) with Mastersizer 2000 (Malvern Instruments)
    • Size distribution

Practice:

  • Sample analysis and practical cases of Dynamic Light Scattering with the Zetasizer Nano ZS (Malvern Instruments) equipment.
  • Samples analysis and practical cases of the Nanoparticle Tracking Analysis (NTA) technique with the Nanosight NS300 (Malvern Instruments) equipment.
  • Sample analysis and practical cases of the Light Scattering (LS) technique with the Mastersizer 2000 (Malvern Instruments) instrument.
• Read More

The first TECNIO Conference and NANBIOSIS’ researchers participation

More than 200 people attended the first edition of the TECNIO Conference that took place on October 19th, 2022 in Girona. Outstanding experts from research groups, companies and the Catalan administration discussed the model of technological sovereignty that Catalonia needs to generate high-impact innovation.

As far as Nora Ventosa, President of the TECNIO Association and Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit (from CIBER-BBN and IQAC): “Political management is the key to ensure that the path of transference follows a high speed train”

Researchers of NANBIOSIS U2 Custom Antibody Service (CAbS) – Nb4D Group from CIBER-BBN and IQAC-CSIC presented their technological offer in the 1st TECNIO Congress

During the congress there were different presentations, round tables and an exhibition space to interact with the TECNIO agents.

For further informatio: https://www.eventbrite.es/e/tecnio-congress-2022-tickets-415838312587

Related News

Nora Ventosa, president of the TECNIO Association.
• Read More

The sprint of the European Project Moore4medical

The NanoBioCel group of the CIBER BBN, which also runs NANBIOSIS U10 Drug Formulation unit , organized the Workshop #6 of the Moore4medical European project at the Alava Technology Park on October 4, 5 and 6

The Central Building of the Álava Technology Park hosted the ‘Workshop #6’ of the European project which. 80 people belonging to 68 organizations, including private companies and research groups from universities and research centers from 13 countries of the European Union, participated in a meeting that has the leadership of the Dutch multinational Philips in its divisions of electronics and medical systems and service innovation

Moore4Medical Project
The three-year Moore4Medical project is funded by the public-private association ECSEL (Electronic Components and Systems for European Leadership), which manages a research and innovation program to strengthen the electronic components and systems sector in order to maintain the European Union at the forefront of technological development. The goal of the project is to accelerate innovation in electronic and microfabricated devices for various emerging medical specialties. The total financing of the project amounts to 68 million euros, of which more than half a million have been granted to the work of NanoBiocel.

NanoBiocel research group

The NanoBiocel research group from UPV/EHU, which is part of the CIBER BBN and the ICTS Nanbiosis through the U10 Drug Formulation, is led by Professor Jose Luis Pedraz, from the Faculty of Pharmacy of the Álava Campus. He participates in the European project Moore4medical on the optimization of the lyophilization process of biopharmaceutical products in microfluidic devices

Microfluidic Device
The University of the Basque Country is working, together with the Mondragón microLIQUID company, on the development of technology for the integration of lyophilized drugs and their rehydration in a microfluidic device for their correct administration. The lyophilized drug will be integrated into the microfluidic device using specific techniques to ensure good interaction between the fluid and the drug for delivery by the pump. The ultimate goal is to design a parenteral drug administration system that is much more comfortable for patients and improves therapeutic compliance with treatments.

The microLIQUID company is a benchmark biotechnological company in the microfluidic technology sector and is responsible for the design and development of microfluidic modules.

In this work called ‘Drug Adherence’, integrated within the total project, the NanoBioCel group has teamed up with the Irish national institute Tyndall, the pharmaceutical multinational AbbVie, the Fraunhofer Institute of Germany, the services innovation section of Philips, the German company Gaudlitz GmbH, specialist in polymers, the Technological Institute Karlsruhe in Germany and the company HI Iberia of Madrid.

• Read More

Biomedicine Project Manager job vacancy

CIBER-BBN is looking for a scientific-technical manager within the framework of the European project H2020 SAFENMT

SafeNMT aims to create an innovative open access platform for companies and laboratories to develop medical solutions based on nanotechnology. The manager will be coordinating the participation of the CIBER ICTS NANBIOSIS units in it, in collaboration with the CIBER-BBN management team, under the leadership of the scientific director of CIBER-BBN and IP of the project.

The position requires good command of English and strong skills in coordinating researchers.

Applications must be filed at CIBER’s weportal untill October 14.

• Read More

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund

September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held asset management firm.
Jaromir Zahrádka, Managing partner of i&i Bio, said: “Nanoligent is the fifth investment of our fund and it belongs to a group of targeted oncology therapies in our portfolio. We are excited by deep scientific background and uniqueness of the technology. The platform is developed by highly motivated, experienced, and fully engaged team of scientists and managers. Based on obtained scientific data, the project has a great potential to become an effective treatment for multiple metastatic-cancer types.”
Nanoligent is focused on the development of new drugs for the treatment of more than 20 different metastatic cancer types. The lead molecule is based on the targeted elimination of cancer cells overexpressing the CXCR4 receptor, a recognized biomarker for poor prognosis and therapy resistance. Nanoligent is developing a new proprietary nano-technological platform, with the potential to overcome current limitations of Antibody-Drug-Conjugates.
“Less than a third of newly diagnosed metastatic patients respond to current therapies, making metastasis one of the most pressing unsolved challenges in cancer. With the support of i&i Bio together with our existing investors, we secure our current milestone to provide the first drug candidate of our portfolio of metastasis-targeted therapies” said Montserrat Cano, CEO of Nanoligent.
 The seed round financing will allow Nanoligent to foster the development of multiple drug candidates and advance the pre-clinical development of its lead candidate in a variety of tumor types.
 “We are happy to welcome the i&i Biotech Fund I in Nanoligent. As in previous cases, we have been impressed by the depth of their scientific due diligence and the professionality of their management. They are going to be an important partner for Nanoligent and we are delighted to continue to co-invest with i&i Bio,” said Michele Marzola who, together with Alessandro Toniolo, are co-champions from IAG in this investment.
Two of the investors already joined the Nanoligent’s Board which includes: Michele Marzola (IAG), Michael Milos (Avanteca Partners), Manuel Rodríguez (Chairman) and Montserrat Cano (CEO).
“The i&i Biotech Fund I is the right partner for the further development of Nanoligent. They have shown in depth scientific knowledge as well as being well connected within the pharmaceutical network. We all together are looking forward to bringing Nanoligent’s development plan effectively to the next stages,” said Michael Milos from AVANTECA Partners.

No alt text provided for this image

About Nanoligent
Nanoligent was founded in 2017 by co-founder and Chairman Manuel Rodriguez Mariscal, as a spin-off coming from more than 10 years of fruitful collaboration between the Nanobiotechnology group – NANBIOSIS U1 PPP at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, co-lead by full professor Antonio Villaverde and Principal Investigator Esther Vázquez, and the Oncogenesis and Antitumor Drug Group – NANBIOSIS U18 Nanotoxicology Unit at the Biomedical Research Institut Sant Pau of the Hospital de la Santa Creu i Sant Pau, headed by full professor Ramon Mangues, the three of them also co-founders of the company. Montserrat Cano joined the company in 2020, with more than 15 years of experience in pharma and biotech companies. The aim of the company is to develop a pioneering technological platform based on protein-drug nanoconjugates to target metastasis across several tumor types. www.nanoligent.com

About Italian Angels for Growth
IAG, founded in 2007, is a leader in the Italian seed venture capital: more than 270 protagonists of the entrepreneurial, financial and industrial world that invest time, skills and capital for the growth of innovative startups. Italian Angels for Growth, in more than ten years of activity, has analyzed more than 6,500 startups and its members have made over 100 investments, for a total of over 300 million euros invested by IAG members and co-investors. IAG business angels support innovative projects financially by investing their own capital, but at the same time, thanks to the mix of skills of the members, support the founders of the startups in the definition of the business model in all its aspects. www.italianangels.net

About AVANTECA Partners
AVANTECA Partners is a Swiss-based, privately held asset management company that invests in early-stage life science companies. www.avanteca.com

About i&i Bio
i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund (see below). With over €45M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to the close cooperation with the fund’s sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies. www.inibio.eu

About European Investment Fund 
i&i Bio is supported by an investment from the EIF, with the support of:

lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and
the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.Nanoligent SL – B66970088

• Read More

NANBIOSIS in the NEW BOOK of the Unique Science and Technology Infrastructures (ICTS)

We are pleased to inform that the new book of Unique Scientific and Technical Infrastructures (ICTS) has been published by the Spanish Ministery of Sciencie and Innovation with the collaborations of the ICTS. You can download it download it here.

The Spanish Map of Unique Science and Technology Infrastructures (ICTS, in Spanish) , goups biomedical technologies, cleanrooms, supercomputers, advanced lasers, telescopes, underground laboratories, synchrotrons, particle accelerators, biological reserves, solar, oceanic and hydraulic platforms, oceanographic research ships, and polar bases in Antarctica. A total of 29 ICTS, made up of 64 infraestructures, allow for ambitious research projects that attract first-rate talent and enhance the technological and innovative industry capacities.

As Diana Morant, Spanish Minister of Science and Innovation says in its prelude “The Unique Science and Technology Infrastructures (ICTS), are crucial for the current country project around science and innovation that we are building together: administrations, research and technology centers, companies and society. I encourage you to go through the pages of this book and discover avant-garde facilities that represent the excellent scientific and technological capabilities that exist today in Spain.”

• Read More

7th Annual Meeting of the Unique Science and Technology Infrastructures in Spain

On September 7, the annual meeting of the directors of the 29 Singular Scientific and Technical Infrastructures (ICTS) of Spain took place in Seville.

The event was organized in five round tables:

Table 1 Development of in-house technology in ICTs and its transfer
Table 2 ICTS response to crisis situations: the COVID19 pandemic and the La Palma volcano eruption
Table 3 Digital Continuum: data management and processing in ICTS
Table 4 Provision of shared ICT Services: connectivity and cybersecurity, implementation of open science in the cloud
Table 5 Stimulation of scientific vocations and social interest in ICTS
Table 6 National and international cooperation between ICTS

The Scientific Director of NANBIOSIS, Jaume Veciana, spoke at Table 5 dedicated to “Stimulation of scientific vocations and social interest in Unique Science and Technology Infrastructures (ICTS)” in which also participated the ICTS Center for Pulsed Lasers, the Astronomical Center Hispanic in Andalusia (CAHA), the National Center for Research on Human Evolution (CENIEH), the Spanish Institute of Oceanography (IEO), the Great Telescope of the CANARY ISLANDS and the Spanish Supercomputing Network (RES).

The meeting was attended by the Minister of Science and Innovation, Diana Morant, who recalled that she remembered that the 29 ICTS contribute to providing solutions from science to present and future challenges and, in addition, are a lever of opportunities throughout the Spanish territory. In total, more than 2,300 people work in these facilities, which have an annual budget of more than 250 million euros.

The minister also highlighted that the reform of the Science, Technology and Innovation Law of September 5, 2022, regulates the for the first time. ICTS Map

• Read More

Philipps-Universität Marburg (Germany) -NANBIOSIS U25 collaboration on the study of tumour microenvironment (TME) changes in Glioblastoma

The scientific coordinator of NANBIOSIS U25 “RNM: Biomedical Application I”, Ana Paula Candiota, was recently awarded with a mobility fellowship from CIBER-BBN for a scientific exchange visit to Philipps-Universität Marburg, in Marburg, Germany.


This scientific stage was motivated for a sustained collaboration between the research groups (GABRMN, in charge of U25 and Neurosurgery Lab group in Marburg), regarding the study of tumour microenvironment (TME) changes in Glioblastoma and possible relationship with the noninvasive MRSI-based biomarkers. Both groups have applied together to different funding calls including ERA-NET Transcan and Pathfinder Open, and Marburg group has hosted a predoctoral stage from a GABRMN PhD student.

The University of Marburg is the university with the longest tradition in Hesse, founded in 1527. With thirteen Leibniz Prize winners, the University of Marburg is one of the leading research institutions in the State of Hesse. Related to the Medicine Faculty of the Philipps University of Marburg is the Uniklinikum Giessend Und Marburg (UKGM), in which the Neurosurgery Lab, lead by Prof. Jörg-Walter Bartsch, is located. This group is hosting Dr. Candiota stage until September 9th.

The main objectives of this short stage are to strength the scientific collaboration, to finish pending work related to TME GL261 glioblastoma, to get familiarized with some approaches used in Marburg and not mastered by GABRMN, and finally to give a talk to group and clinical members, highlighting the potential of U25 and the translational characteristics of the common projects held by both institutions.

• Read More